AzTrials
AzTrials

Advanced Solid TumorPhase 1/2NCT05525247

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination

A Phase 1/2 study testing SLC-3010 and Gemcitabine in people with Advanced Solid Tumor, run by Selecxine at 9 sites in 3 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in patients with… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Advanced Solid Tumor
What is being tested?
SLC-3010 and Gemcitabine
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
27 participants
Where
9 sitesin 3 countries
Study dates
21 Dec 2022to 26 Aug 2025
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients must meet all the following inclusion criteria to be eligible for enrollment into the study:
  • Histologically or cytologically-documented solid tumors that are inoperable locally advanced, metastatic, or recurrent:
  • Part 1 Dose Escalation: Patients with any solid tumor who have progressed on or are intolerant to standard therapy, for which no standard therapy is available, or who decline standard therapy.
  • Part 2: Dose Expansion: Patients must have received at least one prior line of standard therapy in recurrent/metastatic setting and for whom standard life-prolonging therapies are either not available or are not qualified to receive such therapies. Additional general and tumor specific inclusion and exclusion criteria will apply.
  • Patients who have at least one measurable lesion, as defined by RECIST v1.1.
  • Adult male or female patients ≥18 years of age on day of signing the informed consent form (ICF) or follow local regulatory requirement if the legal age for consenting for study participation is more than 18 years.
Show all 29Show fewer
  • Patients who are able and willing to provide written informed consent and are willing and able to comply with all study procedures.
  • Patients with life expectancy of ≥3 months.
  • Patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
  • Patients who demonstrate adequate organ function as defined.
  • Resolution of any clinically significant toxic effects of prior therapy to Grade 0 or 1 according to the NCI CTCAE v5.0 (exception of alopecia and other AEs that are acceptable in the opinion of the Investigator and after discussion with the Medical Monitor)
  • Willingness of male and female patients of reproductive potential to observe conventional and effective birth control methods with failure rates of <1% for the duration of treatment and for 3 months (6 months for female patients administering gemcitabine) following the last dose of study treatment. This must include barrier methods such as condom or diaphragm with spermicidal gel. Women of childbearing potential (WOCBP) are defined as following menarche and who are not postmenopausal (and 2 years of nontherapy-induced amenorrhea or surgically sterile). For male patients with a nonpregnant female partner of childbearing potential and a WOCBP, 1 of the following highly effective birth control methods, with a failure rate of less than 1% per year when used consistently and correctly, is recommended:
  • Combined estrogen and progestin containing hormonal contraception associated with inhibition of ovulation given orally, intravaginally, or transdermally
  • Progestin-only hormonal contraception associated with inhibition of ovulation given orally, by injection, or by implant
  • Intrauterine device
  • Intrauterine hormone-releasing system
  • Bilateral tubal occlusion/ligation
  • Vasectomized partner
  • Sexual abstinence Note: Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the patient.
  • Birth control methods unacceptable for this study include the following:
  • Periodic abstinence (calendar, symptom-thermal, or post-ovulation methods)
  • Withdrawal (coitus interruptus)
  • Spermicide only
  • Lactational amenorrhea method
  • Sperm donation is prohibited during the duration of participation on this protocol and for 90 days after the last dose of study drug
  • WOCBP must have a documented negative serum or urine pregnancy at screening within 3 calendar days before the first dose of study drug. Females who are not of childbearing potential must have documented:
  • Postmenopausal status, defined as cessation of regular menses for at least 12 months and documented serum follicle stimulating hormone (FSH) levels that are within laboratory reference range for postmenopausal women, or
  • Have undergone a documented hysterectomy or bilateral oophorectomy, or
  • Have medically confirmed ovarian failure.

Who cannot join

  • Individuals who meet any of the following exclusion criteria will not be eligible to participate:
  • Prior history of or active malignant disease other than that being treated in this study.
  • Exceptions: (i) Malignancies that were treated curatively and have not recurred within the past 2 years, or (ii) Completely resected basal cell carcinoma and squamous cell carcinoma of the skin, or (iii) Completely resected carcinoma in situ of any type.
  • Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/ or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study drug. Note: patients with an incidental finding of an isolated lesion <1 cm in diameter may be eligible if the lesion does not require treatment per investigator judgment. Eligible patients must be neurologically asymptomatic and without corticosteroids treatment for at least 2 weeks prior to start of first dose of study treatment.
  • Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy, or any immunosuppressive therapy within 7 days prior to first dose of study drug. Topical (<class III), inhaled, nasal, and ophthalmic steroids are allowed.
  • Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
Show all 25Show fewer
  • History of Grade 3 or higher immune mediated AEs that were considered drug related to prior immunotherapy (e.g., checkpoint inhibitors, co-stimulatory agents).
  • Infection with HIV-1 or HIV-2. Active hepatitis B (hepatitis B virus [HBV] surface antigen positive), hepatitis C (hepatitis C virus [HCV] antibody positive, confirmed by HCV ribonucleic acid). Patients with prior history of HBV are eligible if quantitative polymerase chain reaction (PCR) for HBV DNA is negative. Patients with HCV with undetectable virus after treatment, and those who have minimal viral load (<20 IU/ml) at screening and who are being treated with HCV therapy during the full study period are eligible.
  • Has an active infection requiring systemic therapy
  • Has significant cardiovascular disease, such as:
  • QT interval corrected for heart rate using Fridericia's formula > 480 msec at screening
  • History of myocardial infarction, acute coronary syndrome or coronary angioplasty/stenting/bypass grafting within the last 6 months
  • Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV or history of CHF NYHA class III or IV
  • Patients exhibiting significant respiratory symptoms, those with suspected or known serious or severe respiratory conditions and those requiring supplemental oxygen at screening.
  • Receipt of any type of systemic anticancer therapy (including investigational therapy) within 3 weeks before the first dose of study drug or 5 times elimination half-life of drug, if known, has passed whatever is shorter.
  • Is currently participating in or has participated in an interventional clinical trial with last dose of the investigational compound or device within 3 weeks of the first dose of treatment in this current trial. Patients who are in survival follow up can be enrolled if the last dose was 3 weeks earlier.
  • Radiation within 2 weeks before first dose of study treatment. Patients with clinically relevant ongoing complications from prior RT are not eligible.
  • Major surgery within 2 weeks prior to study drug administration; patients must have recovered adequately from toxicity and/ or complications per investigator discretion.
  • Receipt of any live vaccines within 4 weeks prior to first dose of study drug.
  • Receipt of non-live COVID-19 vaccine within 7 days prior to DLT evaluation because vaccine related toxicities could interfere safety assessment.
  • Any prior treatment with IL-2 based drug.
  • Has a known hypersensitivity to the components of the study therapy or its analogs.
  • Has a history or current evidence of any condition therapy, lab abnormality or other circumstance that might expose the patient to risk by participating in the trial, confound the results of the trial, or interfere with the patient's participation for the full duration of the trial.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • For women only: pregnant or breastfeeding

Trial locations and contacts

9 sites in 3 countries.

9 sites in 3 countries

South Korea4 sites

  • Selecxine Investigator site

    Gyeonggi-do, Seongnam-si, 13620

  • Selecxine Investigator site

    Seoul, Jongno-gu, 03080

  • Selecxine Investigator site

    Seoul, Seodaemun-gu, 03722

  • Selecxine Investigator site

    Seoul, Songpa-gu, 05505

Other trials in South Korea

United States3 sites

  • Selecxine Investigator site

    Detroit, Michigan, 48201

  • Selecxine Investigator site

    Oklahoma City, Oklahoma, 73104

  • Selecxine Investigator site

    Sarasota, Florida, 34232

Other trials in United States

Australia2 sites

  • Selecxine Investigator site

    Brentwood, Perth, 6153

  • Selecxine Investigator site

    Waratah, New South Wales, 2298

Other trials in Australia

About this study

Official title: A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination With Various Anticancer Therapies in Patients With Advanced Solid Tumors

This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in patients with various advanced solid tumors.

Being tested
SLC-3010, Gemcitabine
Keywords
IL-2, IL-2/anti-IL-2(TCB2) conjugate, SLC-3010, Immuno-oncology

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SLC-3010Drug

    Intravenous (IV) infusion over 30 minutes on day 1 of each 21-day cycle

  • GemcitabineCombination product

    1000 ㎎/㎡ IV infusion over 30 minutes on day 1 and 8 of each 21-day cycle

Study groups in NCT05525247
Study groupRoleWhat they receive
MonotherapyExperimentalSLC-3010 Intravenous infusion over 30 minutes on day 1 of each 21-day cycle
Receives: Drug: SLC-3010
Gemcitabine combinationExperimentalSLC-3010 Intravenous infusion over 30 minutes on day 1 of each 21-day cycle Gemcitabine 1000 ㎎/㎡ Intravenous infusion over 30 minutes on day 1 and 8 of each 21-day cycle
Receives: Drug: SLC-3010; Combination Product: Gemcitabine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Occurrence of DLTs

    Number of participants with DLTs of SLC-3010 treatment

    Measured: 30 days after last dose

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Sep 2022
  2. Study start21 Dec 2022
  3. Primary completion26 Aug 2025
  4. Study completion26 Aug 2025

Why it stopped: Business decision

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
27 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05525247
Sponsor's protocol ID
SLC-3010-001
Status last verified
Jun 2026
First submitted
23 Aug 2022
Last updated
2 Jul 2026
Results posted
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing SLC-3010 and Gemcitabine in people with Advanced Solid Tumor, run by Selecxine at 9 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 29 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 9 sites in South Korea, United States, Australia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: Business decision). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Occurrence of DLTs (time frame: 30 days after last dose). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05525247.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in